CuraTeQ Biologics' EMA GMP certification marks a key milestone in Aurobindo Pharma's expansion into biosimilars, with three ...

EBR Systems is among ASX healthcare stocks with upcoming catalysts, expecting feedback on a FDA substantive review expected ...

The fact that the European Medicines Agency (EMA) advised against conditional approval adds to the cautious approach. Moreover, Agenus’s ongoing investigator-sponsored trials (ISTs) in the neoadjuvant ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing ...

Neurizon has been buoyed by the receipt of a positive opinion from the European Medicines Agency in relation to its ... Read ...

Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has received a GMP certificate from the European Medicines Agency for its ...

While the final decision is set for next month, biotech player Neurizon’s (ASX:NUZ) hopes have been lifted with a view ...

Global health is likely to be radically altered with Donald Trump in the White House. For starters, the president-elect has ...

Sick people in our country could lose access to essential medicines such as Paracetamol and Metformin (a basic treatment for ...

Indian shares will likely open little changed on Wednesday after a rise in October retail inflation dampened hopes of a rate ...